Cargando…
Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC)
BACKGROUND: Protein used in medicine, e.g. interferon, are immunogenic and quickly broken down by the body. Pegylation is a recognized way of preserving their integrity and reducing immune reactions, and works well with enzymes used to degrade amino acids, a recent focus of attention in controlling...
Autores principales: | Tsui, Sam-Mui, Lam, Wai-Man, Lam, Tin-Lun, Chong, Hiu-Chi, So, Pui-Kin, Kwok, Sui-Yi, Arnold, Simon, Cheng, Paul Ning-Man, Wheatley, Denys N, Lo, Wai-Hung, Leung, Yun-Chung |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2679726/ https://www.ncbi.nlm.nih.gov/pubmed/19374748 http://dx.doi.org/10.1186/1475-2867-9-9 |
Ejemplares similares
-
A phase 1 dose-escalating study of pegylated recombinant human arginase 1 (Peg-rhArg1) in patients with advanced hepatocellular carcinoma
por: Yau, Thomas, et al.
Publicado: (2012) -
Endogenous arginase 2 as a potential biomarker for PEGylated arginase 1 treatment in xenograft models of squamous cell lung carcinoma
por: Lam, Sze-Kwan, et al.
Publicado: (2019) -
Growth suppressive effect of pegylated arginase in malignant pleural mesothelioma xenografts
por: Lam, Sze-Kwan, et al.
Publicado: (2017) -
Inhibition of ornithine decarboxylase 1 facilitates pegylated arginase treatment in lung adenocarcinoma xenograft models
por: Lam, Sze-Kwan, et al.
Publicado: (2018) -
Contactin 1 modulates pegylated arginase resistance in small cell lung cancer through induction of epithelial–mesenchymal transition
por: Xu, Shi, et al.
Publicado: (2019)